Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
309M
-
Number of holders
-
255
-
Total 13F shares, excl. options
-
315M
-
Shares change
-
-2.14M
-
Total reported value, excl. options
-
$3.13B
-
Value change
-
-$32.3M
-
Put/Call ratio
-
1.01
-
Number of buys
-
138
-
Number of sells
-
-106
-
Price
-
$9.92
Significant Holders of AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share (FOLD) as of Q2 2024
303 filings reported holding FOLD - AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share as of Q2 2024.
AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share (FOLD) has 255 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 315M shares
.
Largest 10 shareholders include VANGUARD GROUP INC (28.6M shares), PERCEPTIVE ADVISORS LLC (28.1M shares), Avoro Capital Advisors LLC (27.4M shares), BlackRock Inc. (24.4M shares), WELLINGTON MANAGEMENT GROUP LLP (21.1M shares), JPMORGAN CHASE & CO (14.9M shares), JANUS HENDERSON GROUP PLC (13.2M shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (13M shares), STATE STREET CORP (11M shares), and Redmile Group, LLC (10.6M shares).
This table shows the top 255 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.